Current and potential future drug treatments for osteoporosis.

Patel, Sanjeev

doi:10.1136/ard.55.10.700

Cited by 38 publications

(25 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…About 10% of bone is normally replaced each year [9,10]. Bone metabolism is a continuous cycle of modeling (resorption followed by formation at a distant skeletal site) and remodeling (resorption followed by formation at the same skeletal site).…”

Section: Bone Metabolismmentioning

confidence: 99%

“…Although men do not experience a rapid phase of bone loss, they also have agerelated bone loss. The ultimate outcome depends upon previous peak bone mass and the rate of bone loss [9]. The financial cost of osteoporosis in the U.S. has been estimated as approximately $10 billion each year [9,10].…”

Section: Bone Metabolismmentioning

confidence: 99%

“…For every SD by which BMD is below peak bone mass, fracture risk increases by a factor of 1.5 to 3.0 [9].…”

Section: Bone Metabolismmentioning

confidence: 99%

“…Decreased bone mineral density (BMD), which can lead to fractures, deformity, pain, and a substantial financial burden [9,10], has also been recognized in child cancer patients [11][12][13][14][15][16][17][18][19][20] and, more specifically, acute lymphoblastic leukemia (ALL) patients .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Osteoporosis in Survivors of Acute Lymphoblastic Leukemia

2001

View full text Add to dashboard Cite

Osteoporosis is currently receiving increasing attention as an important late effect in survivors of childhood cancer and its treatment because of their quality of life and its negative effect on the survivors' ability to perform developmentally appropriate activities. Survivors of childhood cancer are especially vulnerable because they are affected during childhood and adolescence, a time when peak bone mass should be achieved. This paper reviews decreased bone density in acute lymphoblastic leukemia (ALL), which is the most common childhood cancer and has a cure rate approaching 80%. Osteopenia/osteoporosis has been observed in all phases of the disease: at diagnosis, during treatment, and throughout the post-treatment period for as long as 20 years. Among the findings that have been described are musculoskeletal pain, disturbed gait, fractures, kyphosis, lordosis, and growth failure. Risk factors not specifically related to ALL include smoking, ingestion of carbonated beverages, and family history of "brittle bone" or fractures. Patients should be counseled in regard to diet, exercise, smoking cessation, and avoidance of carbonated beverages. There are a number of options for specific drug therapy; however, the administration of bisphosponates to children and adolescents must be approached with caution. Research is needed to determine how extensive the problem is and how to best prevent and treat the osteopenia/osteoporosis associated with ALL.

show abstract

Section: Bone Metabolismmentioning

confidence: 99%

Section: Bone Metabolismmentioning

confidence: 99%

“…For every SD by which BMD is below peak bone mass, fracture risk increases by a factor of 1.5 to 3.0 [9].…”

Section: Bone Metabolismmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Osteoporosis in Survivors of Acute Lymphoblastic Leukemia

2001

View full text Add to dashboard Cite

show abstract

“…A osteoporose aparece como a doença de metabolismo ósseo mais comum nos países desenvolvidos, e seu aumento de incidência é tido como um importante problema de saúde pública (PATEL, 1996 A afinidade e difusão da calcitonina nos tecidos duros do dente foram estudadas por Wiebkin et al (1996), onde utilizaram um marcador radioativo para verificar a liberação da calcitonina através da raiz. Nos dentes com o cemento intacto foi necessário um período de 4 a 5 horas para que a calcitonina fosse detectada, porém uma liberação lenta foi observada durante um período de 9 dias.…”

Section: Medicação Intracanal Para Traumatismo Dentáriounclassified

Avaliação in vitro da citotoxicidade do alendronato de sódio sobre fibroblastos de ligamento periodontal de humanos em cultura celular.

Correia¹

View full text Add to dashboard Cite

Risedronate

Crandall¹

2001

Arch Intern Med

View full text Add to dashboard Cite

Risedronate prevents postmenopausal bone loss, decreases fracture in those with established postmenopausal osteoporosis, effectively treats Paget disease, and prevents corticosteroid-induced bone loss. Long-term toxic effects and efficacy, particularly fracture end point data, are unknown. Also undefined are optimal duration of therapy, potential for use in combination with other agents, and direct comparison with other bisphosphonates used for osteoporosis.

show abstract

Current and potential future drug treatments for osteoporosis.

Cited by 38 publications

References 136 publications

Osteoporosis in Survivors of Acute Lymphoblastic Leukemia

Osteoporosis in Survivors of Acute Lymphoblastic Leukemia

Avaliação in vitro da citotoxicidade do alendronato de sódio sobre fibroblastos de ligamento periodontal de humanos em cultura celular.

Risedronate

Contact Info

Product

Resources

About